Predictive factors of survival in patients treated with definitive chemoradiotherapy for squamous cell esophageal carcinoma

World Journal of Gastroenterology

Volumn 12, Issue 26, 2006, Pages 4185-4190

  Di Fiore, Frédéric ^a   Lecleire, Stéphane ^a   Rigal, Olivier ^a   Galais, Marie Pierre ^b   Soussan, Emmanuel Ben ^a   David, Isabelle ^c   Paillot, Bernard ^a   Jacob, Jacques Henri ^b   Michel, Pierre ^a  

^a ROUEN UNIVERSITY HOSPITAL   (France)

^b Genomic and Personalized Medicine in Cancer and Neurological Disorders Unit   (France)

^c CENTRE HENRI BECQUEREL   (France)

Author keywords

Definitive chemoradiotherapy; Esophageal squamous cell carcinoma; Predictive factors

Indexed keywords

CISPLATIN; FLUOROURACIL;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CORRELATION ANALYSIS; DIARRHEA; ESOPHAGITIS; ESOPHAGOSCOPY; ESOPHAGUS CARCINOMA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; MULTIVARIATE ANALYSIS; NAUSEA; NEUROPATHY; NEUTROPENIA; PATIENT SAFETY; PREDICTION; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RADIATION DOSE; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TIME SERIES ANALYSIS; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR VOLUME; UNIVARIATE ANALYSIS; WEIGHT REDUCTION;

EID: 33748584578     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v12.i26.4185     Document Type: Article

References (38)

1. Keighley MR. Gastrointestinal cancers in Europe. Aliment Pharmacol Ther 2003; 18 (Suppl 3): 7-30
2. Menegoz F, Black RJ, Arveux P, Magne V, Ferlay J, Buemi A, Carli PM, Chapelain G, Faivre J, Gignoux M, Grosclaude P, Mace-Lesec'h J, Raverdy N, Schaffer P. Cancer incidence and mortality in France in 1975-95. Eur J Cancer Prev 1997; 6: 442-466
3. Herskovic A, Martz K, al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, Cooper J, Byhardt R, Davis L, Emami B. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992; 326: 1593-1598
4. Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA Jr, Al-Sarraf M, Byhardt R, Russell AH, Beitler JJ, Spencer S, Asbell SO, Graham MV, Leichman LL. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 1999; 281: 1623-1627
5. Bedenne L, Michel P, Bouche O, Triboulet JP, Conroy T, Pezet D, Roullet B, Seitz JF, Lacourt J, Milan C. Randomized phase III trial in locally advanced esophageal cancer: radiochemotherapy followed by surgery versus radiochemotherapy alone (FFCD 9102). Proc Am Soc Clin Oncol 2002; 519a
6. Stahl M, Stuschke M, Lehmann N, Meyer HJ, Walz MK, Seeber S, Klump B, Budach W, Teichmann R, Schmitt M, Schmitt G, Franke C, Wilke H. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005; 23: 2310-2317
7. Burmeister BH, Denham JW, O'Brien M, Jamieson GG, Gill PG, Devitt P, Yeoh E, Hamilton CS, Ackland SP, Lamb DS. Combined modality therapy for esophageal carcinoma: preliminary results from a large Australasian multicenter study. Int J Radiat Oncol Biol Phys 1995; 32: 997-1006
8. Chan A, Wong A. Is combined chemotherapy and radiation therapy equally effective as surgical resection in localized esophageal carcinoma? Int J Radiat Oncol Biol Phys 1999; 45: 265-270
9. Terry P, Lagergren J, Ye W, Nyren O, Wolk A. Antioxidants and cancers of the esophagus and gastric cardia. Int J Cancer 2000; 87: 750-754
10. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003; 349: 2241-2252
11. Rizk NP, Bains MS, Ilson DH, Minsky B, Rush VW. The AJCC Staging System Does Not Predict Survival in Patients Receiving Multimodality Therapy for Esophageal Cancer. Proc Am Soc Clin Oncol 2005, 4005a
12. Seitz JF, Milan C, Giovannini M, Dumas F, Cauvin JM, Conroy T, Francois E, Renard P, Votte-Lambert A, Paillot B, Bedenne L. Concurrent concentrated radio-chemotherapy of epidermoid cancer of the esophagus. Long-term results of a phase II national multicenter trial in 122 non-operable patients (FFCD 8803). Gastroenterol Clin Biol 2000; 24: 201-210
13. Leichman L, Herskovic A, Leichman CG, Lattin PB, Steiger Z, Tapazoglou E, Rosenberg JC, Arbulu A, Asfaw I, Kinzie J. Nonoperative therapy for squamous-cell cancer of the esophagus. J Clin Oncol 1987; 5: 365-370
14. Seitz JF, Giovannini M, Padaut-Cesana J, Fuentes P, Giudicelli R, Gauthier AP, Carcassonne Y. Inoperable nonmetastatic squamous cell carcinoma of the esophagus managed by concomitant chemotherapy (5-fluorouracil and cisplatin) and radiation therapy. Cancer 1990; 66: 214-219
15. Reddy SP, Lad T, Mullane M, Rosen F, Carroll R, Marks JE. Radiotherapy alone compared with radiotherapy and chemotherapy in patients with squamous cell carcinoma of the esophagus. Am J Clin Oncol 1995; 18: 376-381
16. Murakami M, Kuroda Y, Okamoto Y, Kono K, Yoden E, Kusumi F, Hajiro K, Matsusue S, Takeda H. Neoadjuvant concurrent chemoradiotherapy followed by definitive high-dose radiotherapy or surgery for operable thoracic esophageal carcinoma. Int J Radiat Oncol Biol Phys 1998; 40: 1049-1059
17. Minsky BD, Neuberg D, Kelsen DP, Pisansky TM, Ginsberg RJ, Pajak T, Salter M, Benson AB 3rd. Final report of Intergroup Trial 0122 (ECOG PE-289, RTOG 90-12): Phase II trial of neoadjuvant chemotherapy plus concurrent chemotherapy and high-dose radiation for squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys 1999; 43: 517-523
18. Ohtsu A, Boku N, Muro K, Chin K, Muto M, Yoshida S, Satake M, Ishikura S, Ogino T, Miyata Y, Seki S, Kaneko K, Nakumura A. Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol 1999; 17: 2915-2921
19. Hironaka S, Ohtsu A, Boku N, Muto M, Nagashima F, Saito H, Yoshida S, Nishimura M, Haruno M, Ishikura S, Ogino T, Yamamoto S, Ochiai A. Nonrandomized comparison between definitive chemoradiotherapy and radical surgery in patients with T(2-3)N(any) M(0) squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys 2003; 57: 425-433
20. Kaneko K, Ito H, Konishi K, Kurahashi T, Ito T, Katagiri A, Yamamoto T, Kitahara T, Mizutani Y, Ohtsu A, Mitamura K. Definitive chemoradiotherapy for patients with malignant stricture due to T3 or T4 squamous cell carcinoma of the oesophagus. Br J Cancer 2003; 88: 18-24
21. Coia LR, Minsky BD, Berkey BA, John MJ, Haller D, Landry J, Pisansky TM, Willett CG, Hoffman JP, Owen JB, Hanks GE. Outcome of patients receiving radiation for cancer of the esophagus: results of the 1992-1994 Patterns of Care Study. J Clin Oncol 2000; 18: 455-462
22. Forastiere AA, Orringer MB, Perez-Tamayo C, Urba SG, Zahurak M. Preoperative chemoradiation followed by transhiatal esophagectomy for carcinoma of the esophagus: final report. J Clin Oncol 1993; 11: 1118-1123
23. Fujita H, Sueyoshi S, Tanaka T, Tanaka Y, Sasahara H, Shirouzu K, Suzuki G, Hayabuchi N, Inutsuka H. Prospective non-randomized trial comparing esophagectomy-followed-by-chemoradiotherapy versus chemoradiotherapy-followed-by-esophagectomy for T4 esophageal cancers. J Surg Oncol 2005; 90: 209-219
24. Berger AC, Farma J, Scott WJ, Freedman G, Weiner L, Cheng JD, Wang H, Goldberg M. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol 2005; 23: 4330-4337
25. Lim JT, Truong PT, Berthelet E, Pai H, Joe H, Wai E, Larsson S, Kader HA, Weinerman B, Wilson K, Olivotto IA. Endoscopic response predicts for survival and organ preservation after primary chemoradiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys 2003; 57: 1328-1335
26. Tahara M, Ohtsu A, Hironaka S, Boku N, Ishikura S, Miyata Y, Ogino T, Yoshida S. Clinical impact of criteria for complete response (CR) of primary site to treatment of esophageal cancer. Jpn J Clin Oncol 2005; 35: 316-23
27. Ilson DH, Forastiere A, Arquette M, Costa F, Heelan R, Huang Y, Kelsen DP. A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus. Cancer J 2000; 6: 316-323
28. Ajani JA, Walsh G, Komaki R, Morris J, Swisher SG, Putnam JB Jr, Lynch PM, Wu TT, Smythe R, Vaporciyan A, Faust J, Cohen DS, Nivers R, Roth JA. Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction. Cancer 2004; 100: 2347-2354
29. Michel P, Mirabel X, Galais M, Dahan L, Conroy T, Boucher E, Oprea C, Paillot B. Weekly cisplatin/irinotecan and radiotherapy (RT) in patients with locally advanced esophageal cancer: multicenter FFCD phase II trial. Proc Am Soc Clin Oncol 2005, 4060a
30. Thomas CR Jr, Berkey BA, Minsky BD, Gaspar LE, Herskovic A, Rich TA, Gunderson LL. Recursive partitioning analysis of pretreatment variables of 416 patients with locoregional esophageal cancer treated with definitive concomitant chemoradiotherapy on Intergroup and Radiation Therapy Oncology Group trials. Int J Radiat Oncol Biol Phys 2004; 58: 1405-1410
31. Zhang Z, Liao Z, Jin J, Ajani J, Chang JY, Jeter M, Guerrero T, Stevens CW, Swisher S, Ho L, Yao J, Allen P, Cox JD, Komaki R. Dose-response relationship in locoregional control for patients with stage II-III esophageal cancer treated with concurrent chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys 2005; 61: 656-664
32. Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, Okawara G, Rosenthal SA, Kelsen DP. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 2002; 20: 1167-1174
33. Chau I, Norman AR, Cunningham D, Waters JS, Oates J, Ross PJ. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer - pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol 2004; 22: 2395-2403
34. Polee MB, Hop WC, Kok TC, Eskens FA, van der Burg ME, Splinter TA, Siersema PD, Tilanus HW, Stoter G, van der Gaast A. Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy. Br J Cancer 2003; 89: 2045-2050
35. Kato H, Miyazaki T, Nakajima M, Takita J, Kimura H, Faried A, Sohda M, Fukai Y, Masuda N, Fukuchi M, Manda R, Ojima H, Tsukada K, Kuwano H, Oriuchi N, Endo K. The incremental effect of positron emission tomography on diagnostic accuracy in the initial staging of esophageal carcinoma. Cancer 2005; 103: 148-156
36. Flamen P, Van Cutsem E, Lerut A, Cambier JP, Haustermans K, Bormans G, De Leyn P, Van Raemdonck D, De Wever W, Ectors N, Maes A, Mortelmans L. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol 2002; 13: 361-368
37. Wu LF, Wang BZ, Feng JL, Cheng WR, Liu GR, Xu XH, Zheng ZC. Preoperative TN staging of esophageal cancer: comparison of miniprobe ultrasonography, spiral CT and MRI. World J Gastroenterol 2003; 9: 219-224
38. Rice TW. Clinical staging of esophageal carcinoma. CT, EUS, and PET. Chest Surg Clin N Am 2000; 10: 471-485